Management of Type 2 Diabetes with Minimal Kidney Impairment

Introduction to GLP-1 Receptor Agonists

The KDIGO guidelines recommend adding a GLP-1 receptor agonist to metformin as the next best option for patients with type 2 diabetes and chronic kidney disease (CKD) who cannot use SGLT2 inhibitors, as these agents provide cardiovascular and kidney protection, promote weight loss, and carry minimal hypoglycemia risk 1, 3
GLP-1 receptor agonists reduce major adverse cardiovascular events, particularly in patients with established atherosclerotic disease, and reduce albuminuria and slow eGFR decline 1, 3, 5
These agents promote weight reduction and have a low hypoglycemia risk when used without sulfonylureas or insulin 1, 4

Choose agents with documented cardiovascular benefits, such as dulaglutide, liraglutide, and semaglutide, which can be used with minimal dose adjustment in patients with kidney impairment 1
Dulaglutide can be initiated at 0.75 mg weekly and increased to 1.5 mg weekly, with no dose adjustment needed for any level of kidney function 1
Liraglutide can be started at 0.6 mg daily and titrated to 1.2-1.8 mg daily, with no dose adjustment needed 1

If GLP-1 receptor agonists are not covered or not tolerated, consider DPP-4 inhibitors, such as linagliptin, which requires no dose adjustment at any level of kidney function 4
Linagliptin has a favorable safety profile, is body weight neutral, and has a low hypoglycemia risk 4

Assess current eGFR status and reduce metformin dose to half the maximum dose (1000 mg/day maximum) if eGFR is 45-59 mL/min/1.73 m², and monitor eGFR every 3-6 months 1, 4
Discontinue metformin immediately if eGFR is <30 mL/min/1.73 m² 1, 4

Patients with declining kidney function have a 50% reduction in insulin requirements due to decreased renal insulin clearance, increasing the risk of hypoglycemia with insulin secretagogues 4
Do not use thiazolidinediones due to the risk of fluid retention and heart failure, especially with kidney impairment 7
Do not use glyburide due to the risk of severe hypoglycemia caused by its active metabolites accumulating in kidney disease 4